Back to Newsroom

FDA Grants Fast Track Designation to Debiopharm Group’s Antibiotic Debio 1450

Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) granted Fast Track designation to its anti-infectious agent Debio 1450, a highly potent antibiotic specifically active against all Staphylococcus species. FDA Fast Track designation facilitates the development and expedites review of drugs and biologics intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. Debio 1450 has also received designation as a Qualified Infectious Disease Product (QIDP) in September 2014 for the same indication.

Click here to read more